Oppenheimer & Co. Inc. boosted its position in shares of Mediwound Ltd (NASDAQ:MDWD) by 6.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 32,800 shares of the biopharmaceutical company’s stock after purchasing an additional 2,000 shares during the quarter. Oppenheimer & Co. Inc. owned approximately 0.12% of Mediwound worth $164,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Renaissance Technologies LLC raised its holdings in shares of Mediwound by 37.4% in the third quarter. Renaissance Technologies LLC now owns 179,300 shares of the biopharmaceutical company’s stock worth $1,103,000 after acquiring an additional 48,800 shares during the last quarter. ETF Managers Group LLC raised its holdings in shares of Mediwound by 57.4% in the fourth quarter. ETF Managers Group LLC now owns 48,085 shares of the biopharmaceutical company’s stock worth $195,000 after acquiring an additional 17,531 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Mediwound by 33.2% in the fourth quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 17,048 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of Mediwound by 73.5% in the fourth quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 16,840 shares during the last quarter. Finally, Sargent Investment Group LLC acquired a new position in shares of Mediwound in the fourth quarter worth $55,000. Institutional investors own 29.87% of the company’s stock.
Several equities analysts recently commented on MDWD shares. Zacks Investment Research lowered Mediwound from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 16th. Oppenheimer set a $15.00 target price on Mediwound and gave the company a “buy” rating in a research note on Tuesday, January 22nd.
Mediwound (NASDAQ:MDWD) last released its earnings results on Monday, March 25th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.09. The firm had revenue of $0.99 million during the quarter, compared to analyst estimates of $0.80 million. Mediwound had a negative return on equity of 398.49% and a negative net margin of 31.08%. Equities analysts predict that Mediwound Ltd will post -0.57 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/14/mediwound-ltd-mdwd-shares-bought-by-oppenheimer-co-inc.html.
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
See Also: Buyback For Investors Defined
Want to see what other hedge funds are holding MDWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mediwound Ltd (NASDAQ:MDWD).
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.